Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE 68198-5800, USA.
Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE, USA.
Acta Biomater. 2023 Mar 1;158:493-509. doi: 10.1016/j.actbio.2022.12.043. Epub 2022 Dec 26.
Effective antigen delivery facilitates antiviral vaccine success defined by effective immune protective responses against viral exposures. To improve severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) antigen delivery, a controlled biodegradable, stable, biocompatible, and nontoxic polymeric microsphere system was developed for chemically inactivated viral proteins. SARS-CoV-2 proteins encapsulated in polymeric microspheres induced robust antiviral immunity. The viral antigen-loaded microsphere system can preclude the need for repeat administrations, highlighting its potential as an effective vaccine. STATEMENT OF SIGNIFICANCE: Successful SARS-CoV-2 vaccines were developed and quickly approved by the US Food and Drug Administration (FDA). However, each of the vaccines requires boosting as new variants arise. We posit that injectable biodegradable polymers represent a means for the sustained release of emerging viral antigens. The approach offers a means to reduce immunization frequency by predicting viral genomic variability. This strategy could lead to longer-lasting antiviral protective immunity. The current proof-of-concept multipolymer study for SARS-CoV-2 achieve these metrics.
有效的抗原递呈促进了抗病毒疫苗的成功，其定义是针对病毒暴露产生有效的免疫保护反应。为了改善严重急性呼吸综合征冠状病毒 2 型 (SARS-CoV-2) 的抗原递呈，我们开发了一种可控的、可生物降解的、稳定的、生物相容的和无毒的聚合物微球系统，用于化学灭活的病毒蛋白。封装在聚合物微球中的 SARS-CoV-2 蛋白诱导了强大的抗病毒免疫。负载病毒抗原的微球系统可以避免重复给药，突出了其作为有效疫苗的潜力。
成功的 SARS-CoV-2 疫苗已由美国食品和药物管理局 (FDA) 开发并迅速批准。然而，随着新变种的出现，每种疫苗都需要加强。我们假设可注射的生物可降解聚合物代表了一种用于持续释放新兴病毒抗原的方法。该方法提供了一种通过预测病毒基因组变异性来减少免疫接种频率的方法。这种策略可能会导致更持久的抗病毒保护免疫。目前针对 SARS-CoV-2 的多聚合物概念验证研究达到了这些指标。
